Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL62 in Neuromyelitis Optica Spectrum Disorder
NCT05314010Phase 3Active, not recruiting
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Aug 2022
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Bejescin in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Beijing Tianguangshi Pharmaceutical Technology. Started Aug 2022; status: active, not recruiting.
02
Drugs
Bejescin
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05314010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05314010.